CONCLUSION: Levamisole inhibited CD138 expression and affected the levels of IL-6 in a dose-dependent manner. The increased secretion of IL-6 by myeloma cells could be an attempt to protect themselves from apoptosis. RESULTS: Levamisole-mediated growth inhibition of myeloma cells in vitro is associated with a loss of CD138 and increased IL-6 secretion. Alkaline phosphatase assay, Interleukin-6 assay and CD138 expression on myeloma cells by flow cytometry were investigated when the cells were exposed to Levamisole. MATERIAL AND METHODS: U266B1 and RPMI 8226 cell lines were obtained from the National Centre for Cell Sciences, Pune. In this study, we attempted to evaluate the effect of an alkaline phosphatase inhibitor, levamisole on expression of CD138, and level of interleukin-6 (IL-6) in human MM cell lines RPMI 8226 and U266 B1. AIMS AND OBJECTIVES: Despite introduction of many therapeutic agents, the management of multiple myeloma (MM) remains a challenge and search for new therapeutic agents is in progress. CD138 is a transmembrane heparin sulfate glycoprotein expressed on different types of adherent and nonadherent cells.CD138 is used as a standard marker for identification of tumor cells. The myeloma cells have enhanced expression of CD138. This malignancy is characterized by lytic bone disease renal insufficiency, anemia, hypercalcemia, and immunodeficiency. INTRODUCTION: Multiple myeloma (MM) is a B-cell malignancy accounting for 0.8% of all cancer deaths globally.
0 kommentar(er)
